Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioLight Life SciencesBLLSF 18 Cash-to-Debt is 30.67 as of Dec. 2025, which is 60% below its 10-year median of 77.05. GuruFocus rates BLLSF with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,343 Biotechnology companies, BioLight Life Sciences ranks better than 66.2% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioLight Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2025 was 30.67.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioLight Life Sciencescould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for BioLight Life Sciences's Cash-to-Debt or its related term are showing as below:
BLLSF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 22.48 Med: 77.05 Max: No Debt
Current: 30.64
During the past 13 years, BioLight Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 22.48. And the median was 77.05.
BLLSF's Cash-to-Debt is ranked better than 66.2% of 1343
companies
in the Biotechnology industry
Industry Median: 7.25
vs BLLSF: 30.64
BioLight Life Sciences (GREY:BLLSF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
BioLight Life Sciences Cash-to-Debt Related Terms
BioLight Life Sciences Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BLLSF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, BioLight Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLight Life Sciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BioLight Life Sciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLight Life Sciences (BLLSF) has a Cash-to-Debt of 30.67 as of Dec. 2025. This is 60% below median its historical median of 77.05. Over the past decade, BioLight Life Sciences' Cash-to-Debt has ranged from 22.48 to 10,000.00. According to the industry distribution chart, BioLight Life Sciences ranks #454 out of 1343 companies in the Biotechnology industry, placing it in the top 33.8%.
Is BioLight Life Sciences' Cash-to-Debt too high?
BioLight Life Sciences' current Cash-to-Debt of 30.67 is 60% below median its 10-year median of 77.05. Over the past 10 years, this metric has ranged from a low of 22.48 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.25. BioLight Life Sciences' value of 30.67 is 323% above this industry median. Based on the distribution chart, BioLight Life Sciences ranks #454 out of 1343 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioLight Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does BioLight Life Sciences' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLight Life Sciences ranks #454 out of 1343 companies for Cash-to-Debt. This puts BioLight Life Sciences in the upper half of its industry. The industry median Cash-to-Debt is 7.25. BioLight Life Sciences' value of 30.67 is 323% above this benchmark. Historically, BioLight Life Sciences' own Cash-to-Debt has ranged from 22.48 to 10,000.00 over the past decade. While the company's 10-year median is 77.05 vs. the industry median of 7.25, BioLight Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLight Life Sciences's current Cash-to-Debt of 30.67 is 323% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLight Life Sciences's current Cash-to-Debt is 30.67, which is 60% below median its own 10-year median of 77.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLight Life Sciences stock overvalued right now?
BioLight Life Sciences (BLLSF) has a current Cash-to-Debt of 30.67. The current Cash-to-Debt is 30.67, which is 60% below median its 10-year median of 77.05 and 323% above the Biotechnology industry median of 7.25. BioLight Life Sciences' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BioLight Life Sciences (BLLSF), the current Cash-to-Debt is 30.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLight Life Sciences Ltd is an emerging ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.
18GF Score
Get the complete analysis for BLLSF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLSF has been successfully added to your 
